Home

Explore NIH Technologies

Explore work by over 1,500 NIH researchers   |   Available for Licensing & Collaboration

 
 
 
 
 
 
 
 
 
 
 
 
 

Explore Featured Research

Get updates on the latest and most exciting research coming out of NIH...

Read More >

Explore Featured Products

Novel and interesting products coming to market through NIH inventions and partnerships...

Read More >

The National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) are seeking licensees for a personalized tumor vaccine for cancer immunotherapy. Immunologically “cold” tumors have low T-cell infiltration whereas immunologically “hot
Register today for NCI’s webinar on an available COVID-19 vaccine that recently completed a study demonstrating how the vaccine prevented SARS-CoV-2 transmission and infection. Current SARS-CoV-2 vaccines utilize an intramuscular injection, while this technology combines an intramuscular injection
The National Cancer Institute (NCI) is seeking a collaboration partner for a COVID-19 therapeutic that will stop the infected cells from replicating inside a host. When SARS-CoV-2 enters a host, the cells replicate it and viral particles invade the nearby healthy cells. This happens because SARS-CoV